187 related articles for article (PubMed ID: 19950289)
41. Intravenous immunoglobulins improve the function and ameliorate joint involvement in systemic sclerosis: a pilot study.
Nacci F; Righi A; Conforti ML; Miniati I; Fiori G; Martinovic D; Melchiorre D; Sapir T; Blank M; Shoenfeld Y; Pignone AM; Cerinic MM
Ann Rheum Dis; 2007 Jul; 66(7):977-9. PubMed ID: 17344244
[TBL] [Abstract][Full Text] [Related]
42. Therapeutic efficacy of combined glucocorticoid, intravenous cyclophosphamide, and double-filtration plasmapheresis for skin sclerosis in diffuse systemic sclerosis.
Suga K; Yamashita H; Takahashi Y; Katagiri D; Hinoshita F; Kaneko H
Medicine (Baltimore); 2020 Mar; 99(10):e19301. PubMed ID: 32150064
[TBL] [Abstract][Full Text] [Related]
43. Skin involvement in scleroderma--where histological and clinical scores meet.
Verrecchia F; Laboureau J; Verola O; Roos N; Porcher R; Bruneval P; Ertault M; Tiev K; Michel L; Mauviel A; Farge D
Rheumatology (Oxford); 2007 May; 46(5):833-41. PubMed ID: 17255134
[TBL] [Abstract][Full Text] [Related]
44. Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis.
Arnold MB; Khanna D; Denton CP; van Laar JM; Frech TM; Anderson ME; Baron M; Chung L; Fierlbeck G; Lakshminarayanan S; Allanore Y; Riemekasten G; Steen V; Müller-Ladner U; Spotswood H; Burke L; Siegel J; Jahreis A; Furst DE; Pope JE
Rheumatology (Oxford); 2018 Jan; 57(1):152-157. PubMed ID: 29077900
[TBL] [Abstract][Full Text] [Related]
45. Efficacy and safety of methotrexate in articular and cutaneous manifestations of systemic lupus erythematosus.
Islam MN; Hossain M; Haq SA; Alam MN; Ten Klooster PM; Rasker JJ
Int J Rheum Dis; 2012 Feb; 15(1):62-8. PubMed ID: 22324948
[TBL] [Abstract][Full Text] [Related]
46. Efficacy and Safety of Topical Rapamycin in Patients With Facial Angiofibromas Secondary to Tuberous Sclerosis Complex: The TREATMENT Randomized Clinical Trial.
Koenig MK; Bell CS; Hebert AA; Roberson J; Samuels JA; Slopis JM; Tate P; Northrup H;
JAMA Dermatol; 2018 Jul; 154(7):773-780. PubMed ID: 29800048
[TBL] [Abstract][Full Text] [Related]
47. Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group.
Muangchan C; Harding S; Khimdas S; Bonner A; ; Baron M; Pope J
Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1405-14. PubMed ID: 22556030
[TBL] [Abstract][Full Text] [Related]
48. Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis.
Clements PJ; Roth MD; Elashoff R; Tashkin DP; Goldin J; Silver RM; Sterz M; Seibold JR; Schraufnagel D; Simms RW; Bolster M; Wise RA; Steen V; Mayes MD; Connelly K; Metersky M; Furst DE;
Ann Rheum Dis; 2007 Dec; 66(12):1641-7. PubMed ID: 17485423
[TBL] [Abstract][Full Text] [Related]
49. Tofacitinib as a possible treatment for skin thickening in diffuse cutaneous systemic sclerosis.
You H; Xu D; Hou Y; Zhou J; Wang Q; Li M; Zeng X
Rheumatology (Oxford); 2021 May; 60(5):2472-2477. PubMed ID: 33188425
[TBL] [Abstract][Full Text] [Related]
50. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial.
Burt RK; Shah SJ; Dill K; Grant T; Gheorghiade M; Schroeder J; Craig R; Hirano I; Marshall K; Ruderman E; Jovanovic B; Milanetti F; Jain S; Boyce K; Morgan A; Carr J; Barr W
Lancet; 2011 Aug; 378(9790):498-506. PubMed ID: 21777972
[TBL] [Abstract][Full Text] [Related]
51. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial.
van den Hoogen FH; Boerbooms AM; Swaak AJ; Rasker JJ; van Lier HJ; van de Putte LB
Br J Rheumatol; 1996 Apr; 35(4):364-72. PubMed ID: 8624641
[TBL] [Abstract][Full Text] [Related]
52. A randomized, double-blind, placebo-controlled trial: intravenous immunoglobulin treatment in patients with diffuse cutaneous systemic sclerosis.
Takehara K; Ihn H; Sato S
Clin Exp Rheumatol; 2013; 31(2 Suppl 76):151-6. PubMed ID: 23910617
[TBL] [Abstract][Full Text] [Related]
53. Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis.
Spiera R; Kuwana M; Khanna D; Hummers L; Frech TM; Stevens W; Matucci-Cerinic M; Kafaja S; Distler O; Jun JB; Levy Y; Leszcyzński P; Gordon J; Steen V; Lee EB; Jankowski T; Litinsky I; Chung L; Hsu V; Mayes M; Sandorfi N; Simms RW; Finzel S; de Vries-Bouwstra J; Constantine S; Dgetluck N; Dinh Q; Bloom BJ; Furst DE; White B; Denton CP;
Arthritis Rheumatol; 2023 Sep; 75(9):1608-1618. PubMed ID: 37098795
[TBL] [Abstract][Full Text] [Related]
54. Intravenous immunoglobulin may be an effective therapy for refractory, active diffuse cutaneous systemic sclerosis.
Poelman CL; Hummers LK; Wigley FM; Anderson C; Boin F; Shah AA
J Rheumatol; 2015 Feb; 42(2):236-42. PubMed ID: 25433527
[TBL] [Abstract][Full Text] [Related]
55. A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease.
Postlethwaite AE; Wong WK; Clements P; Chatterjee S; Fessler BJ; Kang AH; Korn J; Mayes M; Merkel PA; Molitor JA; Moreland L; Rothfield N; Simms RW; Smith EA; Spiera R; Steen V; Warrington K; White B; Wigley F; Furst DE
Arthritis Rheum; 2008 Jun; 58(6):1810-22. PubMed ID: 18512816
[TBL] [Abstract][Full Text] [Related]
56. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study.
Smith V; Van Praet JT; Vandooren B; Van der Cruyssen B; Naeyaert JM; Decuman S; Elewaut D; De Keyser F
Ann Rheum Dis; 2010 Jan; 69(1):193-7. PubMed ID: 19103636
[TBL] [Abstract][Full Text] [Related]
57. Digital ulcers score: a scoring system to assess digital ulcers in patients suffering from systemic sclerosis.
Ahrens HC; Siegert E; Tomsitz D; Mattat K; March C; Worm M; Riemekasten G
Clin Exp Rheumatol; 2016; 34 Suppl 100(5):142-147. PubMed ID: 27749240
[TBL] [Abstract][Full Text] [Related]
58. Changes in skin score in early diffuse cutaneous systemic sclerosis are associated with changes in global disease severity.
Zheng B; Nevskaya T; Baxter CA; Ramey DR; Pope JE; Baron M;
Rheumatology (Oxford); 2020 Feb; 59(2):398-406. PubMed ID: 31359048
[TBL] [Abstract][Full Text] [Related]
59. A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis.
Derk CT; Grace E; Shenin M; Naik M; Schulz S; Xiong W
Rheumatology (Oxford); 2009 Dec; 48(12):1595-9. PubMed ID: 19846575
[TBL] [Abstract][Full Text] [Related]
60. Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial.
Sircar G; Goswami RP; Sircar D; Ghosh A; Ghosh P
Rheumatology (Oxford); 2018 Dec; 57(12):2106-2113. PubMed ID: 30053212
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
